Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs Against Ebola Virus In Vivo

Version 1 : Received: 8 February 2021 / Approved: 12 February 2021 / Online: 12 February 2021 (08:43:41 CET)

How to cite: Finch, C.L.; Dyall, J.; Xu, S.; Nelson, E.A.; Postnikova, E.; Liang, J.Y.; Zhou, H.; DeWald, L.E.; Thomas, C.J.; Wang, A.; Xu, X.; Hughes, E.; Morris, P.J.; Mirsalis, J.C.; Nguyen, L.H.; Arolfo, M.P.; Koci, B.; Holbrook, M.R.; Hensley, L.E.; Jahrling, P.B.; Schmaljohn, C.; Johansen, L.M.; Olinger, G.G.; Schiffer, J.T.; White, J. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs Against Ebola Virus In Vivo. Preprints 2021, 2021020293 (doi: 10.20944/preprints202102.0293.v1). Finch, C.L.; Dyall, J.; Xu, S.; Nelson, E.A.; Postnikova, E.; Liang, J.Y.; Zhou, H.; DeWald, L.E.; Thomas, C.J.; Wang, A.; Xu, X.; Hughes, E.; Morris, P.J.; Mirsalis, J.C.; Nguyen, L.H.; Arolfo, M.P.; Koci, B.; Holbrook, M.R.; Hensley, L.E.; Jahrling, P.B.; Schmaljohn, C.; Johansen, L.M.; Olinger, G.G.; Schiffer, J.T.; White, J. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs Against Ebola Virus In Vivo. Preprints 2021, 2021020293 (doi: 10.20944/preprints202102.0293.v1).

Abstract

Outbreaks of Ebola ebolavirus (EBOV) have been associated with high morbidity and mortality. Milestones have been reached recently in the management of EBOV disease (EVD) with licensure of an EBOV vaccine and two monoclonal antibody therapies. However, neither vaccines nor therapies are available for other disease-causing filoviruses. In preparation for such outbreaks, and for more facile and cost-effective management of EVD, we seek a cocktail containing orally available and room temperature stable drugs with strong activity against multiple filoviruses. We previously showed that (bepridil + sertraline) and (sertraline + toremifene) synergistically suppress EBOV in cell cultures. Here we describe steps towards testing these combinations in a mouse model of EVD. We identified a vehicle suitable for oral delivery of the component drugs and determined that, thus formulated the drugs are equally active against EBOV as preparations in DMSO, and they maintain activity upon storage in solution for up to seven days. Pharmacokinetic (PK) studies indicated that the drugs in the oral delivery vehicle are well tolerated in mice at the highest doses tested. Collectively the data support advancement of these combinations to tests for synergy in a mouse model of EVD. Moreover, mathematical modeling based on human oral PK projects that the combinations would be more active in humans than their component single drugs.

Subject Areas

filovirus; pandemic preparedness; synergy; viral pathogens; mathematical modeling; projected benefit in humans

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.